Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

The VESALIUS-CV study demonstrated that Amgen's PCSK9 inhibitor, evolocumab (Repatha), significantly reduced major adverse cardiovascular events (MACE) by an absolute 1.8% (HR 0.75) in high-risk patients without a prior history of myocardial infarction or stroke, when used in conjunction with lipid-lowering therapy. This marks the first time a PCSK9 inhibitor has shown such a benefit in a primary prevention population, supporting intensive LDL-cholesterol lowering to approximately 40 mg/dL and providing critical data to bolster the drug's recently expanded FDA indication. The results are expected to broaden the accessibility and clinical application of evolocumab in a substantial high-risk patient cohort, enhancing Amgen's market potential for Repatha.

Analysis

The VESALIUS-CV study marks a significant milestone, being the first to demonstrate that a PCSK9 inhibitor, Amgen's evolocumab (Repatha), can reduce major adverse cardiovascular events (MACE) in high-risk patients without prior myocardial infarction or stroke. Over a median 4.6-year follow-up, evolocumab achieved an absolute risk reduction of 1.8% for the three-point MACE endpoint (HR 0.75) and 2.8% for the four-point endpoint (HR 0.81), alongside a 55% relative reduction in LDL-cholesterol to approximately 45 mg/dL. This robust outcome provides critical clinical validation for aggressive LDL-C lowering in primary prevention.

These positive results directly support the recently expanded FDA indication for evolocumab in primary prevention, addressing a previous lack of specific trial data for this population. The study's findings are expected to broaden the drug's accessibility and clinical application, particularly among the 12,257 high-risk participants, who had a median baseline LDL-C of 122 mg/dL despite high-intensity statin use. The 25% relative MACE reduction in VESALIUS-CV also notably exceeds the 15% reduction observed in the FOURIER trial.

The strong clinical evidence and strengthened regulatory support are poised to significantly enhance Amgen's market potential for Repatha within the substantial primary prevention segment. With no safety issues reported, the trial provides a compelling rationale for clinicians to intensify LDL-C lowering, potentially driving increased adoption and sales for AMGN.